Related Experiment Videos
Development and efficacy assessment of combination vaccines, with emphasis on acellular pertussis
1SmithKline Beecham Biologicals, Rixensart, Belgium.
Insights
New combination vaccines for infants, like DTPa-based combos, require better immune response monitoring. This study proposes using detailed serology and a mouse model to assess protection against whooping cough.
Area of Science:
- Pediatric Vaccinology
- Immunology
- Infectious Disease Prevention
Background:
- Increasing numbers of infant vaccines necessitate combination (combo) vaccines for efficient immunization.
- DTPa vaccines show high efficacy against whooping cough, driving interest in DTPa-based combos (e.g., DTPa-HB-IPV-Hib).
- Established correlates of protection exist for most components of DTPa-combos, except for pertussis.
Purpose of the Study:
- To propose and validate methods for monitoring immune responses to DTPa-combination vaccines.
- To address the lack of a correlate for protection against pertussis in infant immunization.
- To ensure the efficacy of new multi-component infant vaccines.
Main Methods:
- Detailed serological analysis of immune responses in infants receiving DTPa-combos.
- Assessment of cell-mediated immunity markers post-vaccination.
- Utilizing a mouse intranasal challenge model to evaluate vaccine efficacy.
Main Results:
- The study outlines a comprehensive approach to evaluate DTPa-combo immunogenicity.
- Proposed methods aim to establish reliable immune markers for pertussis protection.
- The mouse model provides a platform for preclinical assessment of vaccine effectiveness.
Conclusions:
- Detailed immunological assessments and animal models are crucial for evaluating novel infant combination vaccines.
- This approach will help establish correlates of protection for pertussis, ensuring vaccine efficacy.
- The proposed methods support the development and licensure of advanced DTPa-combos for infant immunization.
Abstract:
The number of vaccines suitable for infant immunization is increasing, leading to a need to co-administer them in combination or combos. The recent demonstration of high efficacy against whooping cough using DTPa vaccines makes it desirable to administer combos such as DTPaHBIPVHib. For all vaccines included, surrogate markers for protection exist, except for pertussis. The field efficacy studies performed with DTPa vaccines did not allow the establishment of a correlate for protection. We propose to use detailed serology and cell-mediated immunity markers obtained from infant immunization studies, as well as a mouse intranasal challenge model, to monitor the immune responses induced by DTPa-combos.